Study of Efficacy and Safety of Laparoscopic Intra-abdominal Chemotherapy (PIPAC) Performed in Patients With Peritoneal Carcinomatosis From Colorectal, Ovarian, Gastric Cancer and Primary Peritoneal Tumors
Single center, open label, phase I-II, non-randomized, two-cohort, repeated single dose study to explore the feasibility, efficacy, safety, and Overall Response Rate (ORR) of oxaliplatin, or cisplatin and doxorubicin when given as a pressurized intraperitoneal chemotherapy (PIPAC) to patients (men and women) with peritoneal carcinomatosis from ovarian, gastric and colorectal cancers and in primary cancers of peritoneum.
Peritoneal Carcinomatosis
DRUG: Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) fixed repeated dose|DRUG: Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) increasing single dose
Overall Response Rate (ORR) according to RECIST criteria (version 1.1) after 2 and 3 cycles of PIPAC., 18 weeks
The overall survival (OS), 30 months|The degree of histological regression assessed by pathological review, 18 weeks|The median time to progression (TTP) according to RECIST criteria (version 1.1) after two or three cycles of PIPAC, 30 months|Measurement of clinical tumor response to therapy using FDG- Positron Emission Tomography (PET) according to PERCIST criteria (version 1.0)., 22 weeks|The Peritoneal Carcinomatosis Index (PCI) before and after therapy, 18 weeks
Single center, open label, phase I-II, non-randomized, two-cohort, repeated single dose study to explore the feasibility, efficacy, safety, and Overall Response Rate (ORR) of oxaliplatin, or cisplatin and doxorubicin when given as a pressurized intraperitoneal chemotherapy (PIPAC) to patients (men and women) with peritoneal carcinomatosis from ovarian, gastric and colorectal cancers and in primary cancers of peritoneum.